The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients

BACKGROUND: Tamoxifen is one of the fundamental pillars of adjuvant endocrine therapy for hormone receptor-positive breast cancer; however, 30–50% of patients receiving tamoxifen experience tumor relapse. CYP2D6, encoded by an extremely polymorphic CYP2D6 gene, is the rate-limiting enzyme of tamoxif...

Descripción completa

Detalles Bibliográficos
Autores principales: Ismail Al-khalil, Wouroud, Al-Salhi, Lana, Rijjal, Sara, Aljamali, Majd, Youssef, Lama A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571463/
https://www.ncbi.nlm.nih.gov/pubmed/36243690
http://dx.doi.org/10.1186/s12885-022-10148-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571463/
https://www.ncbi.nlm.nih.gov/pubmed/36243690
http://dx.doi.org/10.1186/s12885-022-10148-8

Ejemplares similares